Skip to content

Clinical study of Anlotinib as Third-Line or Further Treatment on Advanced Epithelial Ovarian Cancer

Clinical study of Anlotinib as Third-Line or Further Treatment on Advanced Epithelial Ovarian Cancer

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900024312
Enrollment
Unknown
Registered
2019-07-05
Start date
2019-07-03
Completion date
Unknown
Last updated
2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epithelial ovarian cancer

Interventions

Sponsors

Oncology Department, Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18-75 years; (2) Epithelial ovarian cancer was diagnosed by pathology or cytology. (3) The stage of diagnosis is stage IV or after the previous radical treatment, recurrence and metastasis are re-staged to stage IV; (4) After the first-line and second-line treatmentthe tumor progresses again; (5) Behavioral status PS (ECOG) 0-2; (6) The estimated survival time is greater than 3 months; (7) Normal function of bone marrow, liver and kidney: Hb (hemoglobin) >= 80g / L; NEUT (neutrophil count) >= 1.5*10^9 / L; PLT (platelet) >= 90*10^9 / L; Alanine aminotransferase (ALT)= 30g / L; Creatinine (Scr) <= 1.5 * ULN; (8) Knowing to participate in the study, sign the informed consent, good compliance and can follow-up; (9) Women in childbearing age were negative for pregnancy test (blood/urine hCG) within 7 days. And ensured effective contraception during the trial and within 6 months after the end of the trial.

Exclusion criteria

Exclusion criteria: (1) Combined with hypertension and poor drug control, the blood pressure after standard antihypertensive treatment is higher than 140/90mmHg; (2) Combined bleeding risk; (3) Concomitant merger of other malignant tumors within five years; (4) Those who combine active tuberculosis and other serious infectious diseases; (5) Patients who have received radiotherapy; (6) Has received other anti-angiogenic drugs; (7) There are serious brain diseases or mental illnesses that affect the patient's ability to complain privately; (8) With the history of organ transplantation; (9) Participated in other clinical studies within 4 weeks; (10) Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Progression Free Survival;

Secondary

MeasureTime frame
Overall Survival;side effects;

Countries

China

Contacts

Public ContactHaibo Zhang

Guangdong Provincial Hospital of Chinese Medicine

haibozh@aliyun.com+86 13724123615

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026